Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YODKD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BIO-106
|
|||||
| Synonyms |
BIO 106; BIO-106; BIO106
Click to Show/Hide
|
|||||
| Organization |
BiOneCure Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TROP2)
|
Antigen Info | ||||
| Payload Name |
TAMTM
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 study of BIO-106 as monotherapy or in combination with pembrolizumab in patients with advanced cancers (starbridge-1). | ||||
References